SWX:SHLTN

Stock Analysis Report

Executive Summary

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally.

Snowflake

Fundamentals

Flawless balance sheet and good value.


Similar Companies

Share Price & News

How has SHL Telemedicine's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.0%

SHLTN

1.4%

CH Healthcare

-0.8%

CH Market


1 Year Return

-13.4%

SHLTN

-9.7%

CH Healthcare

8.5%

CH Market

Return vs Industry: SHLTN underperformed the Swiss Healthcare industry which returned -9.7% over the past year.

Return vs Market: SHLTN underperformed the Swiss Market which returned 8.5% over the past year.


Shareholder returns

SHLTNIndustryMarket
7 Day7.0%1.4%-0.8%
30 Day1.7%-1.3%-0.8%
90 Day-3.2%-0.8%0.8%
1 Year2.5%-13.4%-8.0%-9.7%14.3%8.5%
3 Year19.9%1.3%-12.5%-16.1%33.6%16.2%
5 Year-11.2%-25.0%39.7%30.5%37.6%16.0%

Price Volatility Vs. Market

How volatile is SHL Telemedicine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SHL Telemedicine undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SHLTN (CHF6.15) is trading below our estimate of fair value (CHF57.79)

Significantly Below Fair Value: SHLTN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SHLTN is good value based on its PE Ratio (12.1x) compared to the Healthcare industry average (25.6x).

PE vs Market: SHLTN is good value based on its PE Ratio (12.1x) compared to the Swiss market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SHLTN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SHLTN is overvalued based on its PB Ratio (2x) compared to the XE Healthcare industry average (2x).


Next Steps

Future Growth

How is SHL Telemedicine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

-5.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SHLTN's earnings are forecast to decline over the next 3 years (-5.5% per year).

Earnings vs Market: SHLTN's earnings are forecast to decline over the next 3 years (-5.5% per year).

High Growth Earnings: SHLTN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: Insufficient data to determine if SHLTN's revenue is forecast to grow faster than the Swiss market.

High Growth Revenue: Insufficient data to determine if SHLTN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SHLTN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has SHL Telemedicine performed over the past 5 years?

30.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SHLTN's earnings have grown significantly by 30.8% per year over the past 5 years.

Accelerating Growth: SHLTN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SHLTN had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Healthcare industry average (5.4%).


Return on Equity

High ROE: SHLTN's Return on Equity (16.5%) is considered low.


Return on Assets

ROA vs Industry: SHLTN has a higher Return on Assets than the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: SHLTN's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is SHL Telemedicine's financial position?


Financial Position Analysis

Short Term Liabilities: SHLTN's short term assets ($17.6M) exceeds its short term liabilities ($16.3M)

Long Term Liabilities: SHLTN's short term assets (17.6M) exceeds its long term liabilities (4.3M)


Debt to Equity History and Analysis

Debt Level: SHLTN's debt to equity ratio (4.5%) is considered satisfactory

Reducing Debt: SHLTN's debt to equity ratio has reduced from 39.4% to 4.5% over the past 5 years.

Debt Coverage: SHLTN's debt is well covered by operating cash flow (1219.8%).

Interest Coverage: SHLTN earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: SHLTN has a low level of unsold assets or inventory.

Debt Coverage by Assets: SHLTN's debt is covered by short term assets (assets are 12.053420x debt).


Next Steps

Dividend

What is SHL Telemedicine's current dividend yield, its reliability and sustainability?

16.06%

Current Dividend Yield


Dividend Yield vs Market

company16.1%marketbottom25%1.9%markettop25%3.7%industryaverage1.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: SHLTN's dividend (16.06%) is higher than the bottom 25% of dividend payers in the Swiss market (1.94%).

High Dividend: SHLTN's dividend (16.06%) is in the top 25% of dividend payers in the Swiss market (3.72%)

Stable Dividend: SHLTN has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: SHLTN's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (194.6%), SHLTN's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of SHL Telemedicine's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Yoav Rubinstein (46yo)

2.5yrs

Tenure

US$1,042,965

Compensation

Mr. Yoav Rubinstein has been the Chief Executive Officer at SHL Telemedicine Ltd. since June 1, 2017. Mr. Rubinstein served as an Investment Manager of Apax Israel Investment Fund. He focused on buyouts an ...


CEO Compensation Analysis

Compensation vs. Market: Yoav's total compensation ($USD1.04M) is about average for companies of similar size in the Swiss market ($USD677.81K).

Compensation vs Earnings: Insufficient data to compare Yoav's compensation with company performance.


Management Age and Tenure

2.5yrs

Average Tenure

Experienced Management: SHLTN's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

0.8yrs

Average Tenure

Experienced Board: SHLTN's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Yoav Rubinstein (46yo)

    Chief Executive Officer

    • Tenure: 2.5yrs
    • Compensation: US$1.04m
  • Yoni Dagan

    Chief Technology Officer

    • Tenure: 2.7yrs
  • Yossi Vadnagra

    Chief Financial Officer

    • Tenure: 2.5yrs
  • Ralf Bork

    Managing Director of SHL Telemedizin

    • Tenure: 0.4yrs

Board Members

  • Erez Nachtomy

    Director

    • Tenure: 0.8yrs
    • Compensation: US$2.54k
  • Dvorah Kimhi

    Independent Director

    • Tenure: 0.8yrs
    • Compensation: US$26.14k
  • Elon Shalev (68yo)

    Director

    • Tenure: 32.8yrs
    • Compensation: US$3.05k
  • Erez Alroy

    Director

    • Tenure: 0.8yrs
    • Compensation: US$2.54k
  • Yariv Alroy

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: US$2.54k
  • Shuky Abramovich (59yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$34.02k
  • Amir Lerman

    Director

    • Tenure: 3.7yrs
    • Compensation: US$27.76k

Company Information

SHL Telemedicine Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SHL Telemedicine Ltd.
  • Ticker: SHLTN
  • Exchange: SWX
  • Founded: 1987
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: CHF64.594m
  • Shares outstanding: 10.50m
  • Website: https://www.shl-telemedicine.com

Number of Employees


Location

  • SHL Telemedicine Ltd.
  • Ashdar Building
  • 90 Yigal Alon Street
  • Tel Aviv
  • 67891
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SHLTNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFNov 2000
SZODB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2000
SMDC.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDNov 2000
SHLTNZBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBCHFNov 2000

Biography

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12-lead  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 20:35
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.